Pfizer’s Outlier Quarter, At Both Extremes
Executive Summary
Investors are trying to wrap their minds around exactly how big Pfizer’s COVID vaccine business will end up being. But they also have questions about Pfizer’s prospects at the opposite end of the patient-population spectrum.
You may also be interested in...
Pfizer DMD Gene Therapy Phase III Trial Stalled In US After FDA Questions On Potency Assays
Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.
CBER Will Staff Up With 100 More Reviewers ‘By Hook Or By Crook,’ Marks Says
US biologics center is getting back to regular business now that COVID-19 work is subsiding; director Marks credits acting commissioner Woodcock with using all available mechanisms to staff up.
Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.